BLFS shows strong growth and a technical breakout, but extreme insider selling failed the engine's insider gate outright, and the stock has already reached its valuation target with an effectively neutral modeled asymmetry.
Thesis pillars
- Fcf Positive Despite Gaap Loss→Stable
- Extreme Insider Selling Gate Failure→Stable
- Strong Revenue Growth And Industry Leadership→Stable
- +2 more pillars — see the Why tab for full reasoning
BioLife Solutions, Inc. (BLFS) Stock Analysis
Range Bound setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $27.19: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 12%; Below-average business quality; Rich valuation.
BioLife Solutions develops, manufactures, and markets bioproduction products for the cell and gene therapy industry, centered on its HypoThermosol FRS and CryoStor biopreservation media alongside cell-processing containers and ThawSTAR automated thawing devices. CryoStor... Read more
Sell if holding. Engine safety override at $27.19: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 12%; Below-average business quality; Rich valuation. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.
Passes 5/8 gates (no SEC red flags, news events none recent, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
About BioLife Solutions, Inc.
About BioLife Solutions, Inc.
CryoStor and HypoThermosol FRS biopreservation media generated approximately 82% of BioLife Solutions' revenue in 2025, with the United States contributing 80% of total revenue and Europe, the Middle East, and Africa another 14%. The company operates two cGMP clean-room production suites in Bothell, Washington for biopreservation media and one in Indianapolis, Indiana for human platelet lysate media.
BioLife earns revenue from direct sales and third-party distributors, with distributor sales accounting for 34% of 2025 revenue, alongside human platelet lysate media, CellSeal and CryoCase closed-system containers, and automated cell-processing and ThawSTAR thawing equipment. Three customers together accounted for approximately 29% of 2025 revenue. The company has narrowed its portfolio through divestitures — selling SAVSU's smart shipping containers in October 2025, Custom Biogenic Systems' cryogenic freezers and SciSafe's cold-chain storage business in late 2024, and Global Cooling's ultra-low-temperature freezers in April 2024 — while acquiring the remaining 90% of PanTHERA CryoSolutions in April 2025 to add patented Ice Recrystallization Inhibitor cryopreservation technology. ThawSTAR devices are produced by a single U.S.-based contract manufacturer that the company estimates would take up to six months to replace.
Show full overview
BioLife's manufacturing depends on suppliers it cannot quickly replace: the company states that for certain components without a secondary supplier, it would take up to six months to find and qualify a second source, and its ThawSTAR automated thawing line relies on a single U.S. contract manufacturer facing the same six-month replacement timeline. That dependency compounds the company's product concentration, since CryoStor and HypoThermosol together generate the large majority of revenue, meaning a supply disruption at either the media manufacturing suites or the ThawSTAR CMO would hit a narrower revenue base than a more diversified life-sciences supplier would face.
See also: Healthcare · Medical Instruments & Supplies
From BioLife Solutions, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCryoStor products82%10-K Item 1A: 'we derived approximately 82%, 80%, and 82% of our revenue from CryoStor products, respectively.'
- MEDIUMCustomertop three customers29%10-K Item 1A: 'we derived approximately 29%, 32%, and 29% of our revenue from three customers, respectively.'
- HIGHGeographicUnited States80%10-K Item 1: 'United States| 80| %'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -2.9%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.19: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 12%; Below-average business quality; Rich valuation. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $25.29. Score 5.5/10, moderate confidence.
Take-profit target: $27.94 (+2.8% upside). Prior stop was $25.29. Stop-loss: $25.29.
Concentration risk — Product: CryoStor products (82.0%); Concentration risk — Geographic: United States (80.0%); Target reached (2.7% upside).
BioLife Solutions, Inc. trades at a P/E of N/A (forward 84.2). TrendMatrix value score: 3.6/10. Verdict: Sell.
15 analysts cover BLFS with a consensus score of 4.2/5. Average price target: $32.
What does BioLife Solutions, Inc. do?BioLife Solutions develops, manufactures, and markets bioproduction products for the cell and gene therapy industry,...
BioLife Solutions develops, manufactures, and markets bioproduction products for the cell and gene therapy industry, centered on its HypoThermosol FRS and CryoStor biopreservation media alongside cell-processing containers and ThawSTAR automated thawing devices. CryoStor products generated approximately 82% of 2025 revenue, with the United States accounting for 80% of total revenue. The company operates cGMP manufacturing suites in Bothell, Washington and Indianapolis, Indiana, and recently divested its SAVSU, CBS, and SciSafe cold-chain businesses to focus on core biopreservation.